Table 3 Summary of outcomes according to mRECIST criteria
Main outcome | N (%) |
|---|---|
Best tumor response | |
 Complete response (CR) | 6 (13.6%) |
 Partial response (PR) | 12 (27.3%) |
 Stable disease (SD) | 10 (22.7%) |
 Progressive disease (PD) | 16 (36.4%) |
DCR | 21 (63.6%) |
ORR | 18 (40.9%) |
Median OS (months) | 27.0 ± 5.8 |
Median PFS (months) | 15.0 ± 2.9 |
1-year OS rate | 83.6% ± 5.7% |
2-year OS rate | 71.3% ± 7.5% |
3-year OS rate | 39.0% ± 9.6% |
1-year PFS rate | 77.0% ± 6.4% |
2-year PFS rate | 63.9% ± 7.5% |
3-year PFS rate | 38.0% ± 8.9% |